Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intramuscular ketamine crossover study in internalizing disorders
ACTRN12619000311156Phase 2Recruiting
- Sponsor
- University of Otago
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ketamine in major depressive disorder (MDD), obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD) and 1 more (4 cohorts), sponsored by University of Otago. Primary endpoints: 10-minute relaxation 16-lead EEG, Clinician-Administered PTSD Scale-5 and 1 more. Started Nov 2020; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)obsessive compulsive disorder (OCD)post-traumatic stress disorder (PTSD)phobic disorder
Beyond the preview
Go deeper on ACTRN12619000311156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000311156.